Qiagen Gains Approval in Japan for EGFR Companion Dx, Acquires Rights to New Markers | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News)– Qiagen today announced that Japanese regulators have approved the company's Therascreen EGFR Mutation Detection Kit as a companion diagnostic for drugs targeting non-small cell lung cancer.

Separately, it also said that it has acquired the rights to biomarkers from two US firms for applications in personalized treatment of various cancers.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: a global genetic interaction map for Saccharomyces cerevisiae, and progress made in genomics, precision medicine, and therapeutics.

The price of plane tickets can affect how scientists in different countries choose to collaborate with each other, NPR reports.

The Annals of Improbable Research has awarded the 2016 Ig Nobel Prizes.

Scientific American alleges that the FDA has been "arm-twisting journalists into relinquishing their reportorial independence."